Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sunho Biologics,Inc. ( (HK:2898) ) has shared an announcement.
Sunho Biologics, Inc. has requested a suspension of trading in its shares on the Hong Kong Stock Exchange, effective from 9:00 a.m. on April 1, 2026. The suspension will remain in place until the company publishes its delayed 2025 annual results, following earlier notices about the postponement of its board meeting and the risk of a trading halt.
The move underscores governance and disclosure pressures on the biotech group, as timely financial reporting is a key requirement for continued listing and investor confidence. Shareholders will be unable to trade the stock during the suspension period, leaving the market awaiting clarity on the company’s 2025 financial performance and any underlying issues behind the delay.
The most recent analyst rating on (HK:2898) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Sunho Biologics,Inc. stock, see the HK:2898 Stock Forecast page.
More about Sunho Biologics,Inc.
Sunho Biologics, Inc. is a biotechnology company listed on the Stock Exchange of Hong Kong under stock code 2898. The company is incorporated in the Cayman Islands with limited liability and is overseen by a board comprising executive, non-executive and independent non-executive directors based in Hong Kong and mainland China.
Average Trading Volume: 9,947
Technical Sentiment Signal: Hold
Current Market Cap: HK$970.4M
See more data about 2898 stock on TipRanks’ Stock Analysis page.